Patients who provided informed consent and voluntarily enrolled
Patients with liver metastasis of advanced colorectal adenocarcinoma with MSS confirmed by pathology;
18-75 years old;
Measurable target lesions according to RECIST V1.1 assessment criteria;
Progression after standard second-line treatment (irinotecan, oxaliplatin, or fluorouracil);
0 \~ 2 points according to ECOG quality of life score;
Drugs can be taken orally
Estimated survival ≥3 months;
Women of childbearing age should comply with contraceptive measures if pregnancy test is negative;
Ascites with no obvious symptoms and no clinical intervention;
Adequate organ and bone marrow functions, ecg, blood, biochemical and other basic tests are not contraindications of chemotherapy;
Adherence to scheduled visits, treatment plans, laboratory tests, and other study procedures Willingness and ability.
You may not be if
Previous application of TAS-102;
Pregnant or lactating women;
No contraception during the reproductive period;
patients known to have a history of allergy to any study drug, similar drug or excipient;
Patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction;
Patients with a history of thromboembolism, except those caused by PICC;
Patients with active infection;
Patients with uncontrolled hypertension (systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥90) MmHg);
Patients with brain metastases with clinical symptoms or imaging evidence;
Contraindications for treatment of other chronic diseases;
Previous immunotherapy-related myocarditis, pneumonia, colitis, hepatitis, kidney Inflammation and other conditions, the current AE is still ≥2;
According to THE NCI CTCAE 5.0 assessment criteria, there are all types of existing cases due to previous treatment Patients with grade ≥2 toxic reactions;
Other conditions that the investigator determines are not suitable for inclusion in the study.
Received any anti-tumor therapy and participated in other clinical studies within 4 weeks prior to enrollment.
